Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection
Free accessResearch articleFirst published online January, 2016
Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection
The efficacy of a direct-acting antiviral agent (DAA) is compromised by the development of drug resistance. The associations between resistance-associated virus (RAV) and therapeutic outcomes have not been well-understood.
Methods
A total of 30 patients with HCV genotype-1b were enrolled and treated for 24 weeks with asunaprevir (ASV) and daclatasvir (DCV). Viral sequences in non-structural (NS) regions 3 and 5A in serum and liver tissue before treatment were examined with direct sequencing, next-generation sequencing (NGS) and the PCR-invader method to evaluate the importance of drug-resistance in the prediction of the outcomes of ASV plus DCV therapy.
Results
Of 30 patients (22 treatment-naive patients, 2 interferon-intolerant patients and 6 non-responders), 25 patients (83.3%) achieved sustained virological response (SVR) 24 weeks after the treatment. Viral breakthrough occurred in three treatment-naive patients and one non-responder. One treatment-naive patient experienced viral relapse. Among 25 patients without RAV, 24 obtained SVR, whereas 5 patients had RAV with a 1.3 to 88% frequency, resulting in various therapeutic outcomes. As for HCV compartments, similar RAVs were detected in serum and liver tissue for a patient obtaining SVR despite HCV NS5A Y93H and another developed viral breakthrough although no RAV was detected. Direct sequencing could not detect RAVs in low frequency (1.3 to 12%) for three of four patients.
Conclusions
Low frequency of RAVs might not affect the outcomes of ASV plus DCV therapy. Deep sequencing and PCR-invader methods can detect clinically significant RAVs for ASV plus DCV therapy.
References
1.
JacobsonI.M., McHutchisonJ.G., DusheikoG.Telaprevir for previously untreated chronic hepatitis C virus infection.N Engl J Med2011; 364: 2405–2416.
ChayamaK., TakahashiS., ToyotaJ.Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.Hepatology2012; 55: 742–748.
6.
SuzukiY., IkedaK., SuzukiF.Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.J Hepatol2013; 58: 655–662.
7.
KumadaH., SuzukiY., IkedaK.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Hepatology2014; 59: 2083–2091.
8.
KarinoY., ToyotaJ., IkedaK.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.J Hepatol2013; 58: 646–654.
9.
KosakaK., ImamuraM., HayesC.N.Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.J Viral Hepat2015; 22: 158–165.
10.
TadokoroK., SuzukiF., KobayashiM.Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.J Virol Methods2011; 171: 67–73.
11.
TadokoroK., SuzukiF., KobayashiM.Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay.Kanzo2014; 55: 720–722.
12.
KanT., HashimotoS., KawabeN.The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.J Gastroenterol2015; in press.
13.
PreciadoM.V., ValvaP., Escobar-GutierrezA.Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.World J Gastroenterol2014; 20: 15992–16013.
14.
MaimoneS., TripodiG., MusolinoC., CacciolaI., PollicinoT., RaimondoG.Lack of the NS5B S282T mutation in HCV isolates from liver tissue of naive patients with HCV genotype-1b infection.Antivir Ther2015; 20: 245–247.
15.
FridellR.A., QiuD., WangC., ValeraL., GaoM.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob Agents Chemother2010; 54: 3641–3650.
16.
BartenschlagerR., LohmannV., PeninF.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Nat Rev Microbiol2013; 11: 482–496.
